Market Cap (In USD)
140.42 Million
Revenue (In USD)
-
Net Income (In USD)
-117.25 Million
Avg. Volume
681.27 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.61-20.21
- PE
- -
- EPS
- -
- Beta Value
- -0.427
- ISIN
- US09077A1060
- CUSIP
- 09077A106
- CIK
- 1840439
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Thomas Andrew Butler
- Employee Count
- -
- Website
- https://biomeafusion.com
- Ipo Date
- 2021-04-16
- Details
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
More Stocks
-
RRX
-
TRT
-
KNSA
-
ALDRVDrone Volt SA
ALDRV
-
TEXMOPIPESTexmo Pipes and Products Limited
TEXMOPIPES
-
SCM
-
1682
-
FFIVF5, Inc.
FFIV